Rapport therapeutics announces appointment of dr. jeffrey sevigny as chief medical officer to drive clinical strategy and precision medicine development

Boston and san diego, march 03, 2025 (globe newswire) -- rapport therapeutics, inc. (nasdaq: rapp), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (cns) disorders, today announced the appointment of dr. jeffrey sevigny as chief medical officer (cmo), effective immediately. a physician-scientist with more than 15 years of leadership in translational and clinical drug development, dr. sevigny has spearheaded groundbreaking research across neuroscience and rare diseases.
RAPP Ratings Summary
RAPP Quant Ranking